中国临床药理学杂志2018，Vol.34Issue(3)：203-205,227,4.DOI:10.13699/j.cnki.1001-6821.2018.03.003
乌司他丁注射剂治疗老年重型颅脑损伤患者的临床研究
Clinical trial of ulinastatin in the treatment of elderly patients with severe craniocerebral brain injury
摘要
Abstract
Objective To observe the effect of different doses of ulinastatin on oxidative stress,immune function and intracranial pressure in elderly patients with severe traumatic brain injury.Methods A total of 117 cases of elderly patients with severe traumatic brain injury were randomly divided into group A (42 cases),group B (38 cases) and group C (37 cases).On the basis of conventional treatment,group A was given ulinastation 1 × 105 U every 12 h.Group B was given ulinastation 2 × 105 U every 12 h.Group C was given ulinastation 4 × 105 U every 12 h.All patients were treatment for 10 d.The levels of oxidative stress indexes,immune function indexes and intracranial pressure and adverse drug reactions among the three groups were observed.Results After treatment,the levels of malondialdehyde (MDA) in A,B,C groups were (12.14 ± 3.56),(8.65 ± 3.41),(5.03 ± 1.94)nmol · L-1.Myeloperoxidase (MPO) levels were (6.35 ± 1.45),(5.27 ± 1.23) and (3.84 ± 1.34) mg · L-1,respectively.Lipid peroxide (LPO) levels were (6.79 ± 2.84),(5.35 ± 2.13) and (4.21 ± 1.39) mg · L-1.The differences of MPO,MDA,LPO levels in each group were statistically significant compared with those in other groups (all P ＜ 0.05).After treatment,CD3 + levels in A,B,C groups were (54.34 ± 8.24) ％,(58.32 ± 9.23) ％ and (63.06 ± 9.76) ％.CD4 + levels were (30.95±3.12)％,(34.53 ± 3.87)％ and (33.97 ± 4.26)％.CD8+ levels were (24.45 ± 4.05)％,(27.56 ±3.34) ％ and(28.37 ±4.53)％.CD4 +/CD8+ were 1.07 ±0.26,1.21 ±0.30 and 1.36 ±0.36,respectively.The differences of CD3 +,CD4 + and CD4 +/CD8 + levels in each group compared with those in other groups were statistically significant (all P ＜ 0.05).The levels of CD8 + had no significant difference between group B and group C (P ＞ 0.05),but there was statistically significant in group A compared with group B and C (P ＜ 0.05).Intracranial pressure on 3,7 and 11 d after treatment of group A were (23.42 ± 3.15),(17.17 ± 3.28),(15.38 ± 4.16) mmHg;group B were (21.25 ±2.83),(15.04 ±3.27),(12.65 ±3.87) mmHg;group C were (18.16 ±3.12),(13.98 ±0.24) and (11.32 ± 1.24) mmHg.The differences of intracranial pressure in three groups were statistically significant (all P ＜ 0.05).The adverse drug reactions in 3 groups during the treatment were leukocyte decrease,rash,pruritus,vascular and elevated alanine aminotransferase,there were no significant differences in adverse drug reactions among 3 groups (all P ＞ 0.05).Conclusion Different doses of ulinastatin have different effects on oxidative stress,immune function and intracranial pressure in elderly patients with severe craniocerebral brain injury,and the application of high dosage has advantages.关键词
乌司他丁注射剂/老年/重型颅脑损伤/氧化应激/免疫功能/颅内压Key words
ulinastatin injection/elderly patient/severe craniocerebral brain injury/oxidative stress/immune function/intracranial pressure分类
医药卫生引用本文复制引用
范宇召,李岫炜,洪军..乌司他丁注射剂治疗老年重型颅脑损伤患者的临床研究[J].中国临床药理学杂志,2018,34(3):203-205,227,4.基金项目
唐山市科技计划基金资助项目(20130939) （20130939）
